bilr-355
Small moleculeexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2002 (NCT02254538)
Timeline
Indications
Mechanism of action
- Cytochrome P450 3A5INHIBITOR
CYP3A5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 11-ethyl-5,11-dihydro-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl)-6h-dipyrido(3,2-b,2',3'-e)(1,4)diazepin-6-one
- 5,11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl)-6h-dipyrido(3,2-b,2',3'-e)(1,4)diazepin-6-one
- 5,11-dihydro-emoddo
- bilr355
- bilr 355
- bilr 355
- bilr 355
- bilr-355
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02253940 | Phase 1 | Oct 1, 2006 | Boehringer Ingelheim |
| NCT02253927 | Phase 1 | May 1, 2006 | Boehringer Ingelheim |
| NCT00294372 | Phase 2 | Feb 1, 2006 | Boehringer Ingelheim |
| NCT02259868 | Phase 1 | Jun 1, 2005 | Boehringer Ingelheim |
| NCT02256826 | Phase 1 | Apr 1, 2005 | Boehringer Ingelheim |
| NCT02253901 | Phase 1 | Mar 1, 2005 | Boehringer Ingelheim |
| NCT02257021 | Phase 1 | Feb 1, 2005 | Boehringer Ingelheim |
| NCT02256774 | Phase 1 | Oct 1, 2004 | Boehringer Ingelheim |
| NCT02253914 | Phase 1 | Feb 1, 2004 | Boehringer Ingelheim |
| NCT02257008 | Phase 1 | Mar 1, 2003 | Boehringer Ingelheim |
| NCT02253953 | Phase 1 | Nov 1, 2002 | Boehringer Ingelheim |
| NCT02254538 | Phase 1 | May 1, 2002 | Boehringer Ingelheim |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 12 | 12 | 2 | 2002 |
1 organizations
Page 1 / 1